State Board of Administration of Florida Retirement System bought a new position in Ignyta, Inc. (NASDAQ:RXDX) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 18,143 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

A number of other large investors also recently bought and sold shares of RXDX. Cutter & CO Brokerage Inc. bought a new stake in Ignyta in the 2nd quarter worth approximately $122,000. Numeric Investors LLC bought a new stake in Ignyta in the 2nd quarter worth approximately $126,000. Legal & General Group Plc grew its position in Ignyta by 71.9% in the 2nd quarter. Legal & General Group Plc now owns 12,681 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 5,306 shares during the period. Virtu KCG Holdings LLC bought a new stake in Ignyta in the 2nd quarter worth approximately $132,000. Finally, Goldman Sachs Group Inc. bought a new stake in Ignyta in the 1st quarter worth approximately $133,000. 71.82% of the stock is owned by institutional investors and hedge funds.

Ignyta, Inc. (NASDAQ RXDX) opened at $16.10 on Wednesday. Ignyta, Inc. has a one year low of $4.60 and a one year high of $18.30. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.07 and a current ratio of 6.07.

Ignyta (NASDAQ:RXDX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.03. analysts expect that Ignyta, Inc. will post -2.31 earnings per share for the current year.

WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/state-board-of-administration-of-florida-retirement-system-takes-position-in-ignyta-inc-rxdx/1719318.html.

A number of research firms have commented on RXDX. Ladenburg Thalmann Financial Services lifted their target price on shares of Ignyta from $20.25 to $31.00 in a research report on Wednesday, October 18th. Cantor Fitzgerald set a $23.00 target price on shares of Ignyta and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Zacks Investment Research raised shares of Ignyta from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Tuesday, November 14th. SunTrust Banks, Inc. began coverage on shares of Ignyta in a research report on Monday. They issued a “buy” rating for the company. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $20.00 target price (up previously from $18.00) on shares of Ignyta in a research report on Thursday, October 12th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $23.80.

Ignyta Company Profile

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.